Roche Official Says Firm Bought NimbleGen To Complement 454; Affy Deal Unaffected

While Roche has provided limited details on how NimbleGen will be integrated into the company, it has maintained that NimbleGen will remain an autonomous business unit of Roche Diagnostics and will continue to operate out of its facilities in Madison, Wis., and Reykjavik, Iceland. The firm is also expected to maintain its branding, like 454 Life Sciences has done so far.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories